1. Home
  2. LABT vs XAIR Comparison

LABT vs XAIR Comparison

Compare LABT & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$2.20

Market Cap

5.3M

Sector

Health Care

ML Signal

N/A

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$3.20

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LABT
XAIR
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.3M
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
LABT
XAIR
Price
$2.20
$3.20
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
350.5K
131.0K
Earning Date
N/A
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,679,000.00
Revenue This Year
N/A
$122.00
Revenue Next Year
N/A
$58.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
107.26
52 Week Low
$1.66
$0.33
52 Week High
$6.85
$8.19

Technical Indicators

Market Signals
Indicator
LABT
XAIR
Relative Strength Index (RSI) 47.73 38.00
Support Level $1.89 $0.59
Resistance Level $2.48 $7.09
Average True Range (ATR) 0.34 0.45
MACD -0.00 -0.19
Stochastic Oscillator 27.02 3.53

Price Performance

Historical Comparison
LABT
XAIR

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Share on Social Networks: